[go: up one dir, main page]

MX2018003096A - Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma. - Google Patents

Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.

Info

Publication number
MX2018003096A
MX2018003096A MX2018003096A MX2018003096A MX2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
preparation
pharmaco
same
composition containing
Prior art date
Application number
MX2018003096A
Other languages
English (en)
Other versions
MX386005B (es
Inventor
Hoon Kim Sang
Hyo SEO Min-
Yeong Nam Hye
Oh Kim Bon-
Yeon Son Ji-
Hye CHOI Ji-
Original Assignee
Samyang Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Biopharmaceuticals filed Critical Samyang Biopharmaceuticals
Priority claimed from PCT/KR2016/010269 external-priority patent/WO2017048018A1/ko
Publication of MX2018003096A publication Critical patent/MX2018003096A/es
Publication of MX386005B publication Critical patent/MX386005B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen una composición farmacéutica para suministro de fármaco aniónico, y un método de preparación para la misma, la composición farmacéutica para suministro de fármaco aniónico que contiene: un fármaco aniónico como un ingrediente activo; un compuesto catiónico; un copolímero de bloque anfifílico; y un polilactato, en donde el fármaco aniónico formó un complejo con el lípido catiónico, y el complejo se encapsula dentro de una estructura micelar formada por el copolímero de bloque anfifílico y el polilactato.
MX2018003096A 2015-09-15 2016-09-12 Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma. MX386005B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150130587 2015-09-15
PCT/KR2016/010269 WO2017048018A1 (ko) 2015-09-15 2016-09-12 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
KR1020160117053A KR101828877B1 (ko) 2015-09-15 2016-09-12 음이온성 약물 함유 약제학적 조성물 및 그 제조방법

Publications (2)

Publication Number Publication Date
MX2018003096A true MX2018003096A (es) 2018-05-11
MX386005B MX386005B (es) 2025-03-18

Family

ID=58496160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003096A MX386005B (es) 2015-09-15 2016-09-12 Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.

Country Status (15)

Country Link
US (2) US11253598B2 (es)
EP (1) EP3357491B1 (es)
JP (1) JP6638072B2 (es)
KR (2) KR101828877B1 (es)
CN (1) CN108024960B (es)
AU (1) AU2016324450B2 (es)
CA (1) CA2998092C (es)
DK (1) DK3357491T3 (es)
ES (1) ES2883290T3 (es)
IL (1) IL257937B (es)
MX (1) MX386005B (es)
PT (1) PT3357491T (es)
RU (1) RU2721558C2 (es)
SG (1) SG11201802073YA (es)
ZA (1) ZA201802303B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366964B (zh) * 2015-12-18 2022-04-08 三养控股公司 制备含阴离子药物的聚合物胶束的方法
KR102175069B1 (ko) * 2017-11-10 2020-11-05 주식회사 삼양바이오팜 음이온성 약물 전달용 지질 나노입자의 동결건조 조성물 및 방법
KR102259513B1 (ko) * 2017-11-16 2021-06-02 주식회사 삼양홀딩스 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법
KR20190127277A (ko) * 2018-05-04 2019-11-13 주식회사 삼양바이오팜 mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법
US20220257679A1 (en) * 2018-08-07 2022-08-18 Samyang Holdings Corporation Polymer nanoparticle composition for delivering virus, and preparation method therefor
CN109136271B (zh) * 2018-09-20 2021-07-20 西北工业大学 阳离子聚乙烯胺线形高分子作为转基因载体的应用
BR112022008849A2 (pt) 2019-11-07 2022-08-23 Samyang Holdings Corp Composição para induzir imunidade a um ingrediente ativo, e, método para preparar uma composição para induzir imunidade a um ingrediente ativo
US20230017360A1 (en) * 2019-11-22 2023-01-19 Samyang Holdings Corporation Kit for preparing nanoparticle composition for drug delivery
CA3162374A1 (en) * 2019-12-20 2021-06-24 So Jin Lee Kit for preparing nanoparticle composition for drug delivery, comprising polylactic acid salt
JP2023528414A (ja) * 2020-06-02 2023-07-04 パーデュー・リサーチ・ファウンデーション 平衡ナノ沈殿による単分散性動力学的凍結ポリマーミセルの製剤
BR112022020991A2 (pt) * 2020-08-31 2023-03-07 Vaim Co Ltd Dispersão de polímero biodegradável, composição compreendendo a mesma e sistema de melhoria da pele
AU2022266457B2 (en) * 2021-04-30 2025-09-04 Samyang Holdings Corporation Kit for preparing nanoparticles containing drug and comprising no amphiphilic polymers
GB202108444D0 (en) * 2021-06-14 2021-07-28 Imperial College Innovations Ltd Sub-micron particle
KR102852074B1 (ko) * 2021-12-23 2025-08-28 주식회사 삼양홀딩스 약물 전달용 지질 및 이를 포함하는 나노입자, 및 이 나노입자를 포함하는 약물 전달용 조성물
KR20230096311A (ko) * 2021-12-23 2023-06-30 주식회사 삼양홀딩스 약물의 폐 전달용 나노입자 조성물
CN114569577B (zh) * 2022-03-07 2023-04-11 晟迪生物医药(苏州)有限公司 一种聚合物包衣纳米粒及其制备方法
KR20250060128A (ko) * 2023-10-24 2025-05-07 주식회사 삼양홀딩스 약물전달용 나노입자의 조성물
KR20250105236A (ko) * 2023-12-29 2025-07-08 주식회사 삼양홀딩스 약물전달용 나노입자의 조성물
KR102893301B1 (ko) * 2024-12-19 2025-12-04 주식회사 에이비파트너스 mRNA 기반 다기능성 단백질 발현 시스템 및 이를 이용한 화장료 조성물
KR102893297B1 (ko) * 2024-12-19 2025-12-04 주식회사 에이비파트너스 다중 기능성 나노복합체를 이용한 활성 성분의 경피 전달 시스템 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
WO2003059382A2 (en) 2001-12-28 2003-07-24 Supratek Pharma Inc. Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
WO2004026453A2 (en) * 2002-09-06 2004-04-01 Genteric, Inc. Microcapsules and methods of use
AU2005239948B9 (en) * 2004-05-06 2009-04-23 Samyang Biopharmaceuticals Corporation Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative
KR100949791B1 (ko) 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
US20090312402A1 (en) * 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
KR20110051214A (ko) * 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체
US20110257253A1 (en) 2008-12-26 2011-10-20 Samyang Corporation Preparation method of polymeric micellar nanoparticles composition containing a poorly water-soluble drug
NZ594245A (en) * 2008-12-26 2013-02-22 Samyang Biopharmaceuticals Pharmaceutical composition containing an anionic drug, a cationic lipid and an amphiphilic block copolymer
KR101296326B1 (ko) * 2009-12-30 2013-08-14 주식회사 삼양바이오팜 폴리락트산을 포함하는 음이온성 약물 전달용 조성물 및 그 제조 방법
WO2012005376A1 (ja) * 2010-07-09 2012-01-12 国立大学法人 東京大学 核酸送達用組成物及び担体組成物、それを用いた医薬組成物、並びに核酸送達方法
WO2012091523A2 (en) 2010-12-30 2012-07-05 Samyang Biopharmaceuticals Corporation Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
PT2833869T (pt) * 2012-04-04 2020-11-25 Samyang Biopharmaceuticals Método de preparação de uma composição para administração de um fármaco aniónico
KR102109188B1 (ko) * 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
EP2983648A4 (en) 2013-04-09 2016-10-12 Univ Georgia COMBINATION THERAPEUTIC NANOPARTICLES

Also Published As

Publication number Publication date
EP3357491A4 (en) 2019-05-08
KR101828877B1 (ko) 2018-02-14
DK3357491T3 (da) 2021-08-02
RU2018113459A (ru) 2019-10-18
KR101948839B1 (ko) 2019-02-15
KR20170032858A (ko) 2017-03-23
RU2721558C2 (ru) 2020-05-20
IL257937A (en) 2018-05-31
CN108024960A (zh) 2018-05-11
US20180250409A1 (en) 2018-09-06
PT3357491T (pt) 2021-08-02
EP3357491A1 (en) 2018-08-08
ES2883290T3 (es) 2021-12-07
US20220125929A1 (en) 2022-04-28
JP2018527413A (ja) 2018-09-20
ZA201802303B (en) 2019-01-30
RU2018113459A3 (es) 2019-10-18
JP6638072B2 (ja) 2020-01-29
IL257937B (en) 2020-10-29
HK1251464A1 (en) 2019-02-01
EP3357491B1 (en) 2021-06-02
SG11201802073YA (en) 2018-04-27
KR20180008854A (ko) 2018-01-24
MX386005B (es) 2025-03-18
CA2998092C (en) 2020-08-04
US11253598B2 (en) 2022-02-22
CA2998092A1 (en) 2017-03-23
AU2016324450A1 (en) 2018-04-12
AU2016324450B2 (en) 2019-04-18
CN108024960B (zh) 2020-12-29

Similar Documents

Publication Publication Date Title
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
CL2020000747A1 (es) Formulaciones de niraparib.
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
CU24520B1 (es) Nanocomplejo micelar de conjugados de polímero-flavonoide para la administración de fármacos antitumorales
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
MX390570B (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
BR112017014996A2 (pt) formulações farmacêuticas e recipientes selados
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
CO2017007316A2 (es) Formulación farmacéutica
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
EA201691741A1 (ru) Фармацевтическая композиция
MX390480B (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
PH12019500992A1 (en) Directly tablettable matrix for producing tablets with extended active substance delivery
ECSP13013095A (es) Composición farmacéutica que comprende fexofenadina
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
NZ702849A (en) Genotype- or phenotype-based drug formulation